CD19 and diffuse large B-cell lymphoma: The reason standing behind this approach was demonstrated in several studies showing higher response rates in patients with r/r B-ALL [41,42], and non-Hodgkin lymphomas, including r/r DLBCL [43,44,45], who received lymphodepleting chemotherapy regimens prior to CD19 CAR-T cells.